Abatacept as a Long-Term Targeted Therapy for LRBA Deficiency

Date
2019
Author
Kutlug, Seyhan
Kapakli, Hasan
Baser, Dilek
Kasap, Nurhan
Altintas, Derya Ufuk
AL-SHAIBI, Ahmad
AGREBI, Nourhen
AYDOGMUS, Cigdem
METIN, Ayse
Aydogan, Metin
Uncuoglu, Aysen
Patiroglu, Turkan
Yildiran, Alisan
Guner, Sukru Nail
Keles, Sevgi
Reisli, Ismail
Somer, Ayper
Guven, Ayla
AYAZ, Nuray
Aksu, Guzide
Charbonnier, Louis Marie
Nain, Ercan
Cekic, Sukru
Kutukculer, Necil
Kilic, Sara S.
Yilmaz, Mustafa
Karakoc-Aydiner, Elif
LO, Bernice
Ozen, Ahmet
Chatila, Talal A.
Baris, Safa
Kara, Manolya
Kiykim, Ayca
ÖĞÜLÜR, İSMAİL
Dursun, Esra
DOĞRUEL, DİLEK
Karaca, Neslihan Edeer
ÇÖĞÜRLÜ, MÜJDE TUBA
BILIR, Ozlem Arman
Cansever, Murat
Metadata
Show full item record
Abstract
BACKGROUND: LPS-responsive beige-like anchor (LRBA) deficiency presents with susceptibility to infections, autoimmunity, and lymphoproliferation. The long-term efficacy of cytotoxic T-lymphocyte-associated antigen 4-immunoglobulin (abatacept) as targeted therapy for its immune dysregulatory features remains to be established.
URI
http://hdl.handle.net/20.500.12627/140411
https://doi.org/10.1016/j.jaip.2019.06.011
Collections